Scilex Holding Presents Poster On ELYXYB At The Annual Scientific Meeting Of The AHS To Be Held On June 13-16, 2024
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding presented a poster on ELYXYB at the Annual Scientific Meeting of the AHS, highlighting its efficacy in treating migraines for patients who do not respond to triptans. The data showed that ELYXYB significantly outperformed placebo in achieving 2-hour pain freedom.
June 13, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex Holding presented positive data on ELYXYB at the AHS meeting, showing significant efficacy in treating migraines for patients unresponsive to triptans.
The presentation of positive Phase 3 trial results for ELYXYB at a major scientific meeting is likely to boost investor confidence in Scilex Holding. The significant efficacy data could lead to increased adoption and sales of ELYXYB, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100